Browsing by Author "Malek, Joel A."

Now showing items 1-8 of 8

    • Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting 

      Abu-Raddad, Laith J.; Chemaitelly, Hiam; Malek, Joel A.; Ahmed, Ayeda A.; Mohamoud, Yasmin A.; ... more authors ( NLM (Medline) , 2021 , Article)
      BACKGROUND: Risk of reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown. We assessed the risk and incidence rate of documented SARS-CoV-2 reinfection in a cohort of laboratory-confirmed ...

    • Discovery of new therapeutic targets in ovarian cancer through identifying significantly non-mutated genes 

      Al-Farsi, Halema; Al-Azwani, Iman; Malek, Joel A.; Chouchane, Lotfi; Rafii, Arash; ... more authors ( BioMed Central Ltd , 2022 , Article)
      Background: Mutated and non-mutated genes interact to drive cancer growth and metastasis. While research has focused on understanding the impact of mutated genes on cancer biology, understanding non-mutated genes that are ...

    • mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar 

      Chemaitelly, Hiam; Yassine, Hadi M.; Benslimane, Fatiha M.; Al Khatib, Hebah A.; Tang, Patrick; ... more authors (2021 , Article)
      The SARS-CoV-2 pandemic continues to be a global health concern. The mRNA-1273 (Moderna) vaccine was reported to have an efficacy of 94.1% at preventing symptomatic COVID-19 due to infection with ‘wild-type’ variants in a ...

    • One Year of SARS-CoV-2: Genomic Characterization of COVID-19 Outbreak in Qatar 

      Benslimane, Fatiha M; Al Khatib, Hebah A; Al-Jamal, Ola; Albatesh, Dana; Boughattas, Sonia; ... more authors ( Frontiers , 2021 , Article)
      Qatar, a country with a strong health system and a diverse population consisting mainly of expatriate residents, has experienced two large waves of COVID-19 outbreak. In this study, we report on 2634 SARS-CoV-2 whole-genome ...

    • Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses. 

      Abu-Raddad, Laith J; Chemaitelly, Hiam; Yassine, Hadi M; Benslimane, Fatiha M; Al Khatib, Hebah A; ... more authors ( Oxford University Press , 2021 , Article)
      Strategies for rolling out vaccination against Coronavirus Disease 2019 (Covid-19) varied across countries. A key question is whether delaying administration of the second vaccine dose to vaccinate the largest number of ...

    • SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy 

      Laith J., Abu-Raddad; Chemaitelly, Hiam; Coyle, Peter; Malek, Joel A.; Ahmed, Ayeda A.; ... more authors ( Elsevier , 2021 , Article)
      Background Reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been documented, raising public health concerns. SARS-CoV-2 reinfections were assessed in a cohort of antibody-positive persons ...

    • The QChip1 knowledgebase and microarray for precision medicine in Qatar 

      Rodriguez-Flores, Juan L.; Messai-Badji, Radja; Robay, Amal; Temanni, Ramzi; Syed, Najeeb; ... more authors ( Nature Research , 2022 , Article)
      Risk genes for Mendelian (single-gene) disorders (SGDs) are consistent across populations, but pathogenic risk variants that cause SGDs are typically population-private. The goal was to develop "QChip1," an inexpensive ...

    • Two prolonged viremic SARS-CoV-2 infections with conserved viral genome for two months 

      Laith J., Abu-Raddad; Chemaitelly, Hiam; Malek, Joel A.; Ahmed, Ayeda A.; Mohamoud, Yasmin A.; ... more authors ( Elsevier , 2021 , Article)
      We document two cases of viremic and prolonged active infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) where the viral genome was conserved for two months, but infection was with little or ...